EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biodexa Pharmaceuticals's Enterprise Value is €82,790.31 Mil.
Biodexa Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.30 Mil. Therefore, Biodexa Pharmaceuticals's EV-to-FCF for today is -11,334.93.
The historical rank and industry rank for Biodexa Pharmaceuticals's EV-to-FCF or its related term are showing as below:
STU:5MP2'
s EV-to-FCF Range Over the Past 10 Years
Min: -11334.93 Med: 0 Max: 0
Current: -11334.93
STU:5MP2's EV-to-FCF is ranked better than 77.58% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs STU:5MP2: -11334.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biodexa Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Biodexa Pharmaceuticals's share price for today is €110400.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biodexa Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-124.165.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5MP2 vs CASIF, OGEN, ELOX: EV-to-FCF Comparison
For the Biotechnology subindustry, Biodexa Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodexa Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biodexa Pharmaceuticals's EV-to-FCF falls into.
Biodexa Pharmaceuticals's current Enterprise Value is €82,790.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biodexa Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodexa Pharmaceuticals (STU:5MP2) has a EV-to-FCF of -11,334.93 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biodexa Pharmaceuticals and its competitors. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #74 out of 330 companies in the Biotechnology industry, placing it in the top 22.4%.
Is Biodexa Pharmaceuticals' EV-to-FCF too high?
Biodexa Pharmaceuticals' current EV-to-FCF is -11,334.93. Based on the distribution chart, Biodexa Pharmaceuticals ranks #74 out of 330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' EV-to-FCF compare to CASIF and OGEN?
According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #74 out of 330 companies for EV-to-FCF. This places Biodexa Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biodexa Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodexa Pharmaceuticals's current EV-to-FCF is -11,334.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current EV-to-FCF of -11,334.93. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current EV-to-FCF is -11,334.93. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current EV-to-FCF is -11,334.93 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued.
The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.
Key valuation signals for STU:5MP2:
EV-to-FCF: -11,334.93
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score
Get the complete analysis for STU:5MP2
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5MP2 has been successfully added to your 
